Jean-Patrick Hennebelle brings 20 years of international pharma and biotech expertise.
Biocodex, an independent French pharmaceutical company with a strong international presence, has announced the appointment of Jean-Patrick Hennebelle as its new Chief Business Development Officer (CBDO), effective June 2025. He now joins the company’s Executive Committee.
Founded in France and active in more than 100 countries through subsidiaries and partners, Biocodex has established itself as a pioneer in the exploration of the intestinal microbiota, making it a strategic focus area. The company develops innovative health solutions across four complementary domains: microbiota, women’s health, rare diseases, and essential healthcare needs such as mental health, sleep, and pain management. With its family-owned identity, industrial footprint in France, and 1,800 employees worldwide, Biocodex aims to combine scientific excellence with international reach and social responsibility.
The appointment of Jean-Patrick Hennebelle reflects Biocodex’s ambition to strengthen its leadership and accelerate external growth and partnership strategies, particularly in its key therapeutic areas. Working closely with CEO Nicolas Coudurier and the Executive Committee, he will oversee the company’s Business Development & Alliances strategy, with a mandate to identify new growth opportunities and support Biocodex’s international expansion.
He succeeds Muriel Avedissian, who will continue to manage alliances with biotech companies. With more than two decades of international experience in external growth and strategic partnerships within the pharmaceutical and biotech industries, Hennebelle previously held senior positions at Ipsen, where he led Business Development for the Late Stage portfolio in Oncology, Rare Diseases, and Neurosciences. His career also includes leadership roles at Expanscience, the French Blood Establishment (EFS), and strategic consulting at EY. He holds a degree in finance from ESCP.
Commenting on the appointment, Nicolas Coudurier, CEO of Biocodex, stated: “The nomination of Jean-Patrick Hennebelle marks a key step in Biocodex’s development. His international expertise, strategic vision, and partnership mindset will be invaluable in accelerating our growth and consolidating our position as an innovative player in the pharmaceutical and biotech sector.”
For his part, Jean-Patrick Hennebelle added: “I am grateful to Biocodex for the trust placed in me. It is with enthusiasm that I join such a committed team, with the ambition to contribute to developing new growth drivers both in France and internationally.”
With this new addition to its leadership team, Biocodex is set to accelerate its external growth and reinforce its long-term vision for innovation in global healthcare, while strengthening its commitment to patients across its key therapeutic areas.